Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
From Visual Field to Visual Field: 10-2 Visual Field Map Prediction from 24-2 Visual Field Using Machine Learning and Detection of Central Visual Field Progression
Author Affiliations & Notes
  • Golnoush Mahmoudinezhad
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, La Jolla, California, United States
  • Sasan Moghimi
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, La Jolla, California, United States
  • Yu Xuan Yong
    Department of Electrical and Computer Engineering, University of California San Diego, La Jolla, California, United States
  • Jiacheng Cheng
    Department of Electrical and Computer Engineering, University of California San Diego, La Jolla, California, United States
  • Liyang Ru
    Department of Electrical and Computer Engineering, University of California San Diego, La Jolla, California, United States
  • Siavash Beheshtaein
    L3Harris Technologies, Torrance, California, United States
  • Evan Walker
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, La Jolla, California, United States
  • Mohsen Adelpour
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, La Jolla, California, United States
  • Leo Meller
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, La Jolla, California, United States
  • Mark Christopher
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, La Jolla, California, United States
  • Jeffrey M. Liebmann
    Bernard and Shirlee Brown Glaucoma Research Laboratory, Department of Ophthalmology, Edward S. Harkness Eye Institute, Columbia University Medical Center, New York, New York, United States
  • Christopher A Girkin
    Department of Ophthalmology and Visual Science, Heersink School of Medicine, University of Alabama-Birmingham, Birmingham, Alabama, United States
  • Massimo A. Fazio
    Department of Ophthalmology and Visual Science, Heersink School of Medicine, University of Alabama-Birmingham, Birmingham, Alabama, United States
  • Linda M Zangwill
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, La Jolla, California, United States
  • Nuno Vasconcelos
    Department of Electrical and Computer Engineering, University of California San Diego, La Jolla, California, United States
  • Robert Weinreb
    Hamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, La Jolla, California, United States
  • Footnotes
    Commercial Relationships   Golnoush Mahmoudinezhad None; Sasan Moghimi Tobacco-Related Disease Research Program T31IP1511 R01EY034148, , Code F (Financial Support); Yu Yong None; Jiacheng Cheng None; Liyang Ru None; Siavash Beheshtaein None; Evan Walker None; Mohsen Adelpour None; Leo Meller None; Mark Christopher None; Jeffrey Liebmann Allergan, Genentech, Thea, Bausch & Lomb, Code C (Consultant/Contractor), Novartis, Research to Prevent Blindness , Code F (Financial Support); Christopher Girkin EY018926, Code F (Financial Support), National Eye Institute,Heidelberg Engineering and Topcon, EyeSight Foundation of Alabama, Research to Prevent Blindness, Heidelberg Engineering, GmbH, Code F (Financial Support); Massimo Fazio National Eye Institute, EyeSight Foundation of Alabama, Research to Prevent Blindness, Heidelberg Engineering, GmbH, Topcon and Wolfram Research, Code F (Financial Support), EY028284, EY026574, Code F (Financial Support); Linda Zangwill Abbvie Inc. Topcon, Code C (Consultant/Contractor), National Eye Institute, Carl Zeiss Meditec Inc., Heidelberg Engineering GmbH, Optovue Inc., Topcon Medical Systems Inc. , Code F (Financial Support), EY027510 (DIGS Myopia) , EY026574 (ADAGESIV), P30EY022589,R01EY034146 (Multimodal AI) , Code F (Financial Support), Zeiss Meditec AISight Health , Code P (Patent); Nuno Vasconcelos Amazon, Nautilus cluster, Code F (Financial Support), National Science Foundation IIS-1924937 IIS-2041009, Code F (Financial Support); Robert Weinreb Abbvie, Alcon, Allergan, Amydis, Equinox, Iantrek, Implandata, IOPtic, , Nicox, Santen, Topcon Medical, Code C (Consultant/Contractor), Topcon Medical, Heidelberg Engineering, Carl Zeiss Meditec, Optovue, Centervue, Zilia, Code F (Financial Support), Toromedes, Carl Zeiss Meditec., Code P (Patent)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 6478. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Golnoush Mahmoudinezhad, Sasan Moghimi, Yu Xuan Yong, Jiacheng Cheng, Liyang Ru, Siavash Beheshtaein, Evan Walker, Mohsen Adelpour, Leo Meller, Mark Christopher, Jeffrey M. Liebmann, Christopher A Girkin, Massimo A. Fazio, Linda M Zangwill, Nuno Vasconcelos, Robert Weinreb; From Visual Field to Visual Field: 10-2 Visual Field Map Prediction from 24-2 Visual Field Using Machine Learning and Detection of Central Visual Field Progression. Invest. Ophthalmol. Vis. Sci. 2024;65(7):6478.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate whether predictions of 10-2 visual field (VF) maps obtained from a machine learning algorithm, called visual field to visual field (V2V), applied to 24-2 VF can detect central VF progression over time.

Methods : This study included 4645 pairs of 10-2 and 24-2 VF tests from 684 participants (1274 eyes). Data was split on the patient level into training (50%), validation (10%) and test sets (40%). Deep learning (DL) algorithm (Multilayer perceptron) and linear regression (LR) models were trained separately on 24-2 VF maps to estimate 10-2 VF 68 total deviation (TD) values and mean deviation (MD) and were compared with each other (Figure1). An independent sample of eyes from the test that had a longitudinal follow-up of at least 5 VFs was selected. The ability of the slope of predicted 10-2 VF MD to detect central VF progression using clustered pointwise linear regression (PLR) was assessed by Receiver operating characteristic (ROC) curves and was compared with the slope of the mean central 12 points of 24-2 VF.

Results : Our LR model predicting 10-2 VF MD achieved R of 0.94 (95% confidence interval [CI], 0.93, 0.95) and MAEs of 1.3 dB (95% CI, 1.2, 1.3) and was comparable to DL estimates of 10-2 MD. The LR model had an average MAE of 2.47 dB (95% CI: 2.39, 2.54) and R of 0.85 (95% CI: 0.84, 0.86) for pointwise TD values estimations and had comparable performance with DL estimates. 193 eyes of 115 patients in the test sample were followed up for an average of 5.2 years and 8 visits. A significant correlation was found between the change over time in V2V predicted and actual 10-2 VF MDs, Figure 2A. The slope of V2V predicted 10-2 VF MD showed an ROC curve area (95% CI) of 0.87 (0.74, 0.94) to discriminate central VF progressors from non-progressors using PLR method which was comparable to actual 10-2 MD slope 0.93 (0.87, 0.97), P=0.19 and was statistically higher than the slope of mean of central 12 points of 24-2 VF 0.77 (0.64, 0.86), P=0.005, Figure2B.

Conclusions : The V2V algorithm estimates 10-2 functional loss from 24-2 VF with high accuracy and potentially could be used to monitor central glaucomatous progression over time. Given the widespread availability of the 24-2 test, this algorithm may lead to improved individualized patient care and risk stratification of patients who are at risk for central VF damage.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×